A Phase II Open Label Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide ISA-51 VG in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence
Brief description of study
The goal of this phase II trial is to evaluate the safety, tolerability, and immunogenicity of vaccination in subjects wiuth melanoma in complete clinical remission but at high-risk for disease recurrence.
Clinical Study Identifier: 10-01711
ClinicalTrials.gov Identifier: NCT10-01711
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
